title: A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.
abstract: BACKGROUND
  We examined the efficacy and safety of three different dosages of venlafaxine hydrochloride (75, 225, and 375 mg/day) in a multicenter, randomized, double-blind, placebo-controlled, four-group study.
  
  
  METHODS
  Outpatients, 18 to 65 years old, who met DSM-III criteria for major depression were included (N = 358 randomized; 194 completed). Of the total patients completing the trial, 59%, 56%, 51%, and 51% were in the placebo, 75-mg, 225-mg, and 375-mg groups, respectively. The primary outcome measures were the Hamilton Rating Scale for Depression (HAM-D21) total, HAM-D21 depression item, Montgomery-Asberg Depression Rating Scale total, and Clinical Global Impressions scale.
  
  
  RESULTS
  Each dosage of venlafaxine was associated with statistically significant improvement as compared with placebo, based on the intent-to-treat sample. The two higher dosages were associated with a modestly greater antidepressant response than was the 75-mg dosage. Nausea, dizziness, somnolence, and anorexia were the most common adverse events attributable to venlafaxine. Since headache occurred at a similar frequency in both the drug and placebo groups, we did not consider it to be attributable to venlafaxine use. Withdrawal from the study due to adverse events occurred in 5%, 17%, 24%, and 30% of the patients in the placebo, 75-mg, 225-mg, and 375-mg groups, respectively.
  
  
  CONCLUSIONS
  Venlafaxine, at dosages of 75-375 mg/day, is an effective and well-tolerated antidepressant. With increasing dosage, greater efficacy and possibly more adverse effects will occur.
authors.affiliation: Clinical Research and Development, Wyeth-Ayerst Research, Radnor, PA, USA.
authors.forename: R L
authors.initials: RL
authors.lastname: Rudolph
authors.forename: L F
authors.initials: LF
authors.lastname: Fabre
authors.forename: J P
authors.initials: JP
authors.lastname: Feighner
authors.forename: K
authors.initials: K
authors.lastname: Rickels
authors.forename: R
authors.initials: R
authors.lastname: Entsuah
authors.forename: A T
authors.initials: AT
authors.lastname: Derivan
mesh_terms: D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000855:Anorexia / Q000139:chemically induced; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003511:Cyclohexanols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004244:Dizziness / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012893:Sleep Wake Disorders / Q000139:chemically induced; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D010919:Placebos; D000069470:Venlafaxine Hydrochloride